Brochure More information from http://www.researchandmarkets.com/reports/3533727/ Chronic Plaque Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016 Description: SUMMARY The Report, Chronic Plaque Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Chronic Plaque Psoriasis Report is to understand the market and pipeline status of the drugs around the Chronic Plaque Psoriasis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Chronic Plaque Psoriasis. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India. Please note:this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. SCOPE: - A snapshot of the global Market and Phase III therapeutics scenario for Chronic Plaque Psoriasis. - A review of the marketed products under prescription for Chronic Plaque Psoriasis, regulatory information and marketing status. - Coverage of global patent coverage and detailed commentaries on the US patent challenges. - Graphical representation of investigational products for patent expiry and market exclusivities across the globe. - Product profiles for marketed products for Chronic Plaque Psoriasis with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. - Coverage of API Manufacturers for Chronic Plaque Psoriasis drugs in the United States, Europe and Asian Regions with location details. - Coverage of Regulatory filings in theus, Europe, and Asia specifically India and China for Chronic Plaque Psoriasis drugs. - Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Chronic Plaque Psoriasis drugs. - Coverage of Chronic Plaque Psoriasis Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress. - Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs. - Key discontinued Marketed products. - Global Sales Figure to 2018. Reasons to buy - Evaluate the marketing status and exclusivity details of Chronic Plaque Psoriasis key products to exploit opportunities for generic drug development opportunities. - Identify and understand important and diverse types of therapeutics under Phase III development for Chronic Plaque Psoriasis. - Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Chronic Plaque Psoriasis. - API intelligence over marketed drugs forchronic Plaque Psoriasisand gaining primary intelligence over active ingredients manufacturers across the globe. - API intelligence over leading Phase III Pipeline drugs. - Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope. - Understanding the scope of the Phase III Drugs with nil regulatory filings. - Understanding the chemical route of synthesis of approved drugs for Chronic Plaque Psoriasis. - Uncovering opportunities in the rapidly growing US market.
Contents: 1. Indication Overview 2. Market Drugs Landscape 2.1 Marketed Drugs 2.2 Marketed Details of Drugs by Application Type 2.3 Marketed Details of Drugs (NDA) by Marketing Status 2.4 Marketed Details of Drugs by Patent Expiration Timeline 3. Global API Manufacturers Assessment 3.1 API Manufacturers by United States Drug Master File (US DMF) Status 3.2 API Manufacturers by US DMF Status (Drug Specific) 3.3 API Manufacturers in Europe by Country 3.4 API Manufacturers in India by State 3.5 API Manufacturers in China by Province 3.6 Marketed Details of Approved Drugs by Geography 4. Phase III Drugs Landscape 4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs 4.2 API Manufacturers by US DMF Status (Drug Specific) 5. Drugs Market Data and Forecasted Sales Figure-2018 6. Marketed Drugs for Chronic Plaque Psoriasis 6.1 Drug Name 6.1.1 Drug Description 6.1.2 Global Active Pharmaceutical Manufacturers for Drug 6.1.3 Approval Status of Drug 6.1.4 Patent and Exclusivity Details for Drug 6.1.5 Company Profile and Financials 7. Phase III Drugs for Chronic Plaque Psoriasis 7.1 Drug Name 7.1.1 Drug Description 7.1.2 United States Drug Master File (DMF) 8. Discontinued Drugs for Chronic Plaque Psoriasis 9. Appendix 10. Methodology 11. Consulting Services 12. Contact Us 13. Disclaimer List of Tables - Chronic Plaque Psoriasis Therapeutic Market, US, Marketed Drugs by Application Type, 2016 - Chronic Plaque Psoriasis Therapeutic Market, US, Marketed Drugs by Marketing Status, 2016 - Chronic Plaque Psoriasis Therapeutic Market, US, (Year), 2016 - Chronic Plaque Psoriasis Marketed Drugs, API Manufacturers by US DMF Status, 2016 - Chronic Plaque Psoriasis Marketed Drugs, US DMF Status Drug Specific (Number), 2016 - Chronic Plaque Psoriasis Drugs, API Manufacturers, Europe by Country, 2016 - Chronic Plaque Psoriasis Drugs, API Manufacturers, India by State, 2016 - Chronic Plaque Psoriasis Drugs, API Manufacturers, China by Province, 2016 - Chronic Plaque Psoriasis Drugs, API Manufacturers by Geography 2016 - Chronic Plaque Psoriasis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016 - Chronic Plaque Psoriasis Therapeutic Market, Global Sales-2018 (in million USD) - API Manufacturers for Drug, 2016 - Phase III Drugs for Chronic Plaque Psoriasis, 2016 - Discontinued Drugs for Chronic Plaque Psoriasis, 2016 List of Figures
- Chronic Plaque Psoriasis Therapeutic Market, US, Marketed Drugs by Application Type (%), 2016 - Chronic Plaque Psoriasis Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2016 - Chronic Plaque Psoriasis Therapeutic Market, US, (Year), 2016 - Chronic Plaque Psoriasis Marketed Drugs, API Manufacturers by US DMF Status (%), 2016 - Chronic Plaque Psoriasis Marketed Drugs, US DMF Status Drug Specific (Number), 2016 - Chronic Plaque Psoriasis Drugs, API Manufacturers, Europe by Country, 2016 - Chronic Plaque Psoriasis Drugs, API Manufacturers, India by State, 2016 - Chronic Plaque Psoriasis Drugs, API Manufacturers, China by Province, 2016 - Chronic Plaque Psoriasis Drugs, API Manufacturers by Geography 2016 - Chronic Plaque Psoriasis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016 - Chronic Plaque Psoriasis Therapeutic Market, Global Sales 2018 (in million USD) - Drug, Patent/Exclusivity Expiry (Year), 2016 Ordering: Order Online - http://www.researchandmarkets.com/reports/3533727/ Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8,
Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/ Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Web Address: Office Code: Chronic Plaque Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016 http://www.researchandmarkets.com/reports/3533727/ SC Product Formats Please select the product formats and quantity you require: Single User: Site License: Enterprisewide: Quantity USD 2000 USD 4000 USD 6000 Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Email Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Pay by wire transfer: Please transfer funds to: Account number 833 130 83 Sort code 98-53-30 Swift code IBAN number Bank Address ULSBIE2D IE78ULSB98533083313083 Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World